EDMONTON, May 1 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), aleading developer in the treatment of multiple sclerosis (MS), today announcedthat Mr. Kevin Giese, President and CEO, BioMS Medical and Buu Le Lien, SeniorManager, Corporate Business Development, Eli Lilly and Company, will take partin a speciality panel session at BioFinance 2008 in Toronto entitled "Anatomyof a Deal - BioMS Medical and Eli Lilly and Company."
Also participating in the panel session will be Nitin Kaushal, ManagingDirector, Desjardins Securities and Jeremy Webster, Executive Vice President &Director, Deloitte & Touche. The moderator for the session will be CherylReicin, Partner, Torys LLP.
Kevin Giese will also provide a corporate presentation at 11:00am (EasternTime) on Wednesday May 7th.
About BioFinance 2008
BioFinance 2008 is the Canadian Life Science industry's leading investorconference. The meeting brings together key industry players to considerinvestment opportunities and issues affecting companies in biotechnology,medical devices, diagnostics and research tools. Participants include seniorlife science executives, institutional and venture capital investors, industryanalysts, corporate finance executives and experts from the scientific andmedical communities in Canada, the United States, Europe and Asia. For moreinformation visit http://www.biofinance.ca/
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development andcommercialization of novel therapeutic technologies. BioMS Medical's leadtechnology, MBP8298, is for the treatment of multiple sclerosis and is beingevaluated in two pivotal phase III clinical trials for secondary progressiveMS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the UnitedStates. It additionally is being evaluated for relapsing remitting MS patientsin a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMSentered into a licensing and development agreement granting Eli Lilly andCompany exclusive worldwide rights to MBP8298 in exchange for an $87 millionupfront payment, milestone payments and escalating royalties on sales. Forfurther information please visit our website at www.biomsmedical.com.
This press release may contain forward-looking statements, which reflectthe Company's current expectation regarding future events. Theseforward-looking statements involve risks and uncertainties that may causeactual results, events or developments to be materially different from anyfuture results, events or developments expressed or implied by suchforward-looking statements. Such factors include, but are not limited to,changing market conditions, the successful and timely completion of clinicalstudies, the establishment of corporate alliances, the impact of competitiveproducts and pricing, new product development, uncertainties related to theregulatory approval process and other risks detailed from time to time in theCompany's ongoing quarterly and annual reporting. Certain of the assumptionsmade in preparing forward-looking statements include but are not limited tothe following: that MBP8298 will continue to demonstrate a satisfactory safetyprofile in ongoing and future clinical trials; and that BioMS Medical Corp.will complete the respective clinical trials within the timelines communicatedin this release. We undertake no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise.WHEN: Wednesday May 7th @ 3:00 PM (Eastern Time) WHERE: Toronto Marriott, Toronto
SOURCE BioMS Medical Corp.